Antiviral compounds

• US 8,809,266 B2
• Filed: 03/11/2013
• Issued: 08/19/2014
• Est. Priority Date: 06/29/2007
• Status: Expired due to Fees

• Current Assignee: Gilead Sciences Inc.
• Original Assignee: Gilead Sciences Inc.
• Inventors: Cho, Aesop, Clarke, Michael O'Neil Hanrahan, Kim, Choung U., Link, John O., Pyun, Hyung-jung, Sheng, Xiaoning C., Wu, Qiaoyin
• Primary Examiner(s): HEARD, THOMAS SWEENEY
• Application Number:
  US13/794,389
• Publication Number:
  US 20130274439A1
• Time in Patent Office: 526 Days
• Field of Search: None
• US Class Current: 514/4.3
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: C07D 207/16 Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 403/14 containing three or more hetero rings
• CPC Class Codes: C07D 413/14 containing three or more hetero rings
• CPC Class Codes: C07D 417/14 containing three or more hetero rings
• CPC Class Codes: C07D 487/04 Ortho-condensed systems
• CPC Class Codes: C07K 5/0804 and aliphatic
• CPC Class Codes: C07K 5/0808 the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
• CPC Class Codes: C07K 5/0819 with the first amino acid being acidic
• CPC Class Codes: C07K 5/0821 with the first amino acid being heterocyclic, e.g. His, Pro, Trp

Abstract

The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

Claims

1. A compound selected from the group consisting of:

3. A method of treating hepatitis C, said method comprising administering to an individual in need thereof a pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

4. The method of claim 3, wherein the pharmaceutical composition further comprises at least one additional therapeutic agent.

5. The method of claim 4, wherein the additional therapeutic agent is selected from the group consisting of interferons, ribavirin analogues, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, and non-nucleoside inhibitors of HCV.

6. The method of claim 3, wherein the pharmaceutical composition further comprises a nucleoside analogue.

7. The method of claim 6, wherein the pharmaceutical composition further comprises an interferon or pegylated interferon.

8. The method of claim 6, wherein the nucleoside analogue is selected from the group consisting of ribavirin, viramidine, levovirin, a L-nucleoside, and isatoribine.

2. A compound selected from the group consisting of:

9. A method of treating hepatitis C, said method comprising administering to an individual in need thereof a pharmaceutical composition which comprises a therapeutically effective amount of a compound of claim 2 or a pharmaceutically acceptable salt thereof.

10. The method of claim 9, wherein the pharmaceutical composition further comprises at least one additional therapeutic agent.

11. The method of claim 10, wherein the additional therapeutic agent is selected from the group consisting of interferons, ribavirin analogues, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, and non-nucleoside inhibitors of HCV.

12. The method of claim 9, wherein the pharmaceutical composition further comprises a nucleoside analogue.

13. The method of claim 12, wherein the pharmaceutical composition further comprises an interferon or pegylated interferon.

14. The method of claim 12, wherein the nucleoside analogue is selected from the group consisting of ribavirin, viramidine, levovirin, a L-nucleoside, and isatoribine.